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Hypospadias (an abnormal opening of the ure-
thra) and cryptorchidism (a failure of one or
both testicles to descend) are two relatively com-
mon male genital congenital anomalies, occur-
ring in 35 of 10,000 and 40 of 10,000 births,
respectively (Paulozzi 1999). Recent evidence
has suggested that hypospadias and cryptor-
chidism have increased in frequency in some
populations (Paulozzi 1999). This is of public
health signiﬁcance, particularly because of the
well-known association between cryptorchidism
and testicular cancer (Wilson and Foster 1985;
Toppari et al. 1996), which also appears to be
on the increase (Toppari et al. 1996).
In mammals, cryptorchidism depends on
mullerian-inhibiting hormone, androgens,
and intra-abdominal pressure (Wilson and
Foster 1985). The formation of the male
external genitalia in utero also occurs under
the influence of androgens (Baskin et al.
2001). There is suggestion that increasing rates
of hypospadias and cryptorchidism may be
caused partly by early exposure to endocrine-
disrupting chemicals in the environment (Beard
et al. 1984; Berkowitz et al. 1995; Depue 1984;
Hjertkvist et al. 1989; Jackson 1988; Landrigan
et al. 2003; McBride et al. 1991; Sharpe and
Skakkebaek 1993; Sweet et al. 1974; Swerdlow
et al. 1983; Toppari et al. 1996). This hypothe-
sis is supported by the higher rates of urogeni-
tal anomalies, including cryptorchidism, in
studies of sons exposed in utero to diethyl-
stilbestrol, a potent estrogen (Cosgrove et al.
1977; Gill et al. 1979).
Although the use of one potent environ-
mental endocrine disruptor, dichlorodiphenyl-
trichloroethane (DDT), has been banned in
the United States since 1972, concerns about
its potential health effects continue because of
its worldwide use in the eradication of malaria,
its accumulation in the human food chain, and
its long half-life in human tissues due to its
lipophilicity (Clarkson 1995). DDT functions
as an exogenous estrogen (Bulger and Kupfer
1983) and, in animal studies, has been shown
to suppress Leydig cell development, alter secre-
tion of mullerian-inhibiting substance by the
Sertoli cells, and cause negative feedback inhibi-
tion at the fetal pituitary gland (Sharpe and
Skakkebaek 1993). p,p´-Dichlorodiphenyl-
dichloroethylene (DDE), the persistent
metabolite of p,p´-dichlorodiphenyltrichloro-
ethane (DDT), acts as an androgen receptor
antagonist at target tissues and has been shown
to inhibit the action of testosterone (Danzo
1997; Kelce et al. 1995). DDT or DDE may
alter sex hormone metabolism, reducing avail-
able testosterone to tissues (Guillette et al.
1995). Adverse reproductive system effects asso-
ciated with in utero DDT or DDE exposure in
male animals include abnormal development of
ovarian tissue (Fry and Toone 1981), reduced
penis size (Guillette and Guillette 1996),
reduced testosterone levels (Subramanian et al.
1987), reduced male rat anogenital distance
(Gray et al. 2001), hypospadias (Gray et al.
2001), cryptorchidism (Facemire et al. 1995;
Gray et al. 2001), impaired reproductive capac-
ity (Bowerman et al. 1995), low sperm density
(Facemire et al. 1995), and abnormal sperm
(Facemire et al. 1995).
Few epidemiologic studies provide infor-
mation on the relationship between male
reproductive disorders and organochlorine
insecticides in humans. García-Rodríguez et al.
(1996) found higher rates of orchidopexy (a
surgical procedure to correct cryptorchidism)
in districts in Spain with more intensive farm-
ing. However, Longnecker et al. (2002) found
no clear evidence of an effect of DDE on
hypospadias or cryptorchidism among subjects
in the Collaborative Perinatal Project. We
report on an analysis of serum levels of DDT
and DDE in a nested case–control study of
cryptorchidism and hypospadias in a longitu-
dinal cohort of pregnancies that occurred
between 1959 and 1967, a period when DDT
was produced and used in the United States
but before the beginning of the rise in preva-
lence of hypospadias in the United States
(Baskin et al. 2001).
Materials and Methods
The Child Health and Development Studies
(CHDS) is a longitudinal cohort study of
20,754 pregnancies among women enrolled
in the San Francisco Bay Area Kaiser Foun-
dation Health Plan between 1959 and 1967
(van den Berg et al. 1988). Nearly 92% of all
eligible pregnancies invited to participate
were included in the cohort. Subscribers
to this prepaid health plan represented an
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Pregnant women were interviewed shortly
after recruitment and later during their preg-
nancies. Maternal and pediatric medical records
were abstracted throughout the follow-up
period. Abstracted records contained informa-
tion from every child visit until at least 5 years
of age, including physician’s diagnosis and
treatment, test results, and anthropometric
measures (Christianson et al. 1981). Children
averaged at least three visits per year from birth
until 5 years of age. The study’s rate of attrition
was extremely low; the CHDS observed 89.4%
of live-born children until 5 years of age.
The ascertainment of congenital anomalies
occurred through routine medical procedures
and practices and appropriate specialized tests
and referrals. The CHDS itself did not imple-
ment any additional routine or special tests to
ascertain congenital anomalies. At least two
physicians and one biostatistician reviewed
abstracted information to ensure uniform
recording. Congenital anomalies were classi-
fied based on the International Classification
of Diseases, 7th Revision [World Health
Organization (WHO) 1957]. An anomaly
was coded as deﬁnite only if a physician con-
sidered the diagnosis certain or if confirmed
by surgery or laboratory tests. Abstracted
data were subsequently computer coded
(Christianson et al. 1981).
Blood samples were obtained from the
pregnant women at the time of enrollment,
during each subsequent trimester, and imme-
diately after delivery. At least one sample was
obtained for 89% of pregnancies. Serum sam-
ples were subsequently divided into a package
of four 2-mL vials and stored at –20°C at the
National Institutes of Health (Bethesda, MD).
For this nested case–control study, we
used a subset of males who were followed by
the CHDS for at least 2 years and for whom
computer records showed that at least one
serum sample had been collected and stored.
We restricted the subset to this minimum
length of follow-up because cryptorchidism
was coded by CHDS as an anomaly only if it
persisted until 2 years of age.
Among the 9,345 males followed until
2 years of age, 101 had cryptorchidism, 73
had hypospadias, and 6 had both. We were
able to obtain serum from the mothers of
75 subjects with cryptorchidism, 66 subjects
with hypospadias, and 4 subjects with both
conditions. We randomly selected 283 con-
trols from the remaining male singleton births
who were followed to 2 years of age, did not
have hypospadias or cryptorchidism, and had
one recorded serum sample. There were no
matching criteria for controls.
Laboratory assays. If available, the serum
conservators provided the last pregnancy serum
of the mother (n = 86); otherwise, samples
from the postpartum period were provided
(n = 334). Given the long half-life of DDT
and DDE and the high correlation among
DDE levels measured at different times during
gestation (Longnecker et al. 1999), these serum
samples should accurately reﬂect body burdens
over the entire pregnancy. National Cancer
Institute staff in Frederick, Maryland, retrieved
the requested archived serum, placed a 1.5-mL
aliquot of the sample into a separate vial,
assigned a study identification number, and
shipped the samples overnight on dry ice to the
Hazardous Materials Laboratory of the State of
California in Berkeley, California, where they
were stored at below –20°C until laboratory
analysis. Standard quality assurance procedures
included rigorous calibration procedures, trace-
ability of all standards, and internal review and
audit. Method (reagent) blanks and laboratory
controls were performed on either 10% of
the samples or at least one with every batch of
samples, whichever was greater. Internal stan-
dard recovery was performed on every chemi-
cal group on every sample. The laboratory staff
were blind to the identity of the samples and to
case/control status.
Laboratory personnel performed analyses in
batches of 12 samples. Each batch consisted of
nine study subject samples, one method blank,
one laboratory control (fortiﬁed bovine serum),
and a standard reference material [SRM 1589a,
a human serum from the National Institute of
Standards and Technology (Gaithersburg,
MD)]. Batches included a consistent propor-
tion of cases and controls. Unbeknown to labo-
ratory staff, some batches included samples of
pooled CHDS serum in place of a study subject
sample to assess performance and to also facili-
tate future interlaboratory standardization.
Analytical methods are described in detail
elsewhere (Petreas et al. 2003). Brieﬂy, serum
was thawed, and 1 mL was pipetted into a
15-mL test tube. Internal standards [polychlori-
nated biphenyl (PCB) congeners 14, 65, and
166 and tetrachloromethyl xylene (TCMX;
AccuStandard, Inc., New Haven, CT)] were
added before denaturing the proteins with 1 mL
of acetic acid (Fisher Scientiﬁc, Pittsburgh, PA).
Solvents employed were nanograde isooctane
(Mallinckrodt, Paris, KY), trace environmental
analysis grade hexane (99.9%), methanol
(99.9%), dichloromethane (99.9%), pesticide
residue grade acetone (99.9%), and toluene
(99.9%) (Burdick & Jackson, Muskegon, MI).
The analytes in the serum were then extracted
with hexane:dichloromethane (90:10, vol:vol),
and the extract was passed through a glass
column ﬁlled with Florisil. The analytes were
eluted with hexane followed by hexane:
dichloromethane (1:1, vol:vol). The eluates
were combined and concentrated, and recovery
standards (pentachloronitrobenzene, PCB-30,
PCB-204, and PCB-209) were added. We used
six-level calibration curves with concentrations
encompassing expected ranges for each analyte.
Analysis was performed by gas chromatography/
electron capture detection (Hewlett Packard
6890; Agilent Technologies, Palo Alto, CA)
equipped with 60-m DB-XLB (Agilent Tech-
nologies) and Rtx-5ms capillary gas chro-
matography columns (Resick Corporation,
Bellefonte, PA). Total lipids were calculated
from total cholesterol and triglycerides (Phillips
et al. 1989). We determined total cholesterol
and triglycerides enzymatically in a small ali-
quot of serum at the Clinical and Epidemio-
logical Research Laboratory, Boston Children’s
Hospital (Boston, MA), and results were
reported both as nanograms per milliliter of
serum and as nanograms per gram lipid.
We used recoveries of internal standards
(PCB-14, PCB-65, PCB-166 and TCMX) to
gauge overall data quality for all analytes across
all serum batches. Recoveries were between 81
and 99%, and no corrections were made to
the measurements. Control charts on the per-
formance of the laboratory controls (reagent
blanks, fortified bovine serum, and SRM
1589a) were maintained for all analytes across
all batches to ensure that results were within
quality control (QC) criteria. Of the samples
analyzed, 420 were from participants and 20
were blind laboratory controls interspersed
among the actual samples serving as external
QC controls. The identity of the 20 external
QC controls was revealed only at the end of
the analyses, and results were used to assess
precision among batches. Based on these
external QC samples, within-batch precision
[expressed as the intrabatch coefﬁcient of vari-
ation (CV%)] was 2.71% for DDT and
3.01% for DDE. The interbatch CV% was
9.97% for DDT and 9.11% for DDE.
Statistical methods. Preliminary analyses
involved univariate examination of serum meas-
ures and covariates of interest using summary
statistics. Among the available CHDS informa-
tion, we selected variables known from the liter-
ature to be related to exposures or outcomes as
potential covariates: maternal age, prepregnancy
body mass index (BMI), parity, maternal ethnic-
ity, maternal place of birth, maternal occupation
before pregnancy, birth weight, gestational age,
date of blood draw, and season of birth. We
plotted the cumulative distribution as well as
density and quintile plots. We performed bivari-
ate analysis of covariates and case/control status
using logistic regression. We performed bivari-
ate analysis between covariates and the distrib-
ution of serum measures using linear regression
for continuous variables and analysis of vari-
ance for categorical variables. Because 25%
of all observations were missing either height
or prepregnancy weight, we imputed the
prepregnancy BMI for those women who
were missing only prepregnancy weight by
calculating median weight gained during
pregnancy for women in each pregnancy BMI
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the women whose weight was measured at the
same point during their pregnancy.
We examined the relationship between
exposure and case status for both cryptorchidism
and hypospadias using logistic regression. For
models that included serum measures as contin-
uous variables, we used log-transformed values.
For categorical analysis, we identiﬁed quartile
cut points based on the distribution of each
measure among the whole study sample. All
regression analyses included cholesterol and
triglycerides (milligrams per deciliter serum) as
separate continuous variables.
We included all covariates in a backward
stepwise elimination model (exclusion criteria
p < 0.20) to evaluate the influence of these
potential confounders on the effect of expo-
sures to DDT or DDE on cryptorchidism
and hypospadias. Separate models were evalu-
ated for cryptorchidism and for hypospadias;
models for all cases combined were also exam-
ined. Finally, we assessed the effect of the
ratio of DDE to DDT on the outcomes as a
way to evaluate the effect of recentness of
exposure to DDT. All analyses were per-
formed using the open source statistical pro-
gram RGui, version 1.3.1 (R Foundation for
Statistical Computing, Vienna, Austria).
Results
Most maternal, child, and delivery characteris-
tics examined were similar among cases and
controls (Table 1); a higher proportion of
hypospadias cases were born to white mothers,
and mothers with offspring with cryptor-
chidism had higher prepregnancy BMI than
did control mothers. Mean DDE and DDT
levels, whether expressed as a serum concentra-
tion (nanograms per milliliter serum) or lipid
adjusted (micrograms per gram lipid), did not
differ among cryptorchidism cases, hypo-
spadias cases, and controls (Table 2).
Women whose serum DDE level was in
the highest quartile (> 61.0 ng/mL) had no
increased risk [adjusted odds ratio (OR) = 1.02;
95% confidence interval (CI), 0.50–2.09;
p-value for trend = 0.89] of giving birth
to a case, compared with women whose 
serum DDE level was in the lowest quartile
(< 27.0 ng/mL) after adjusting for cholesterol
and triglycerides (Table 3). The only variable
that met the inclusion criteria of p < 0.20 in
the backward stepwise regression was mater-
nal race. Although the OR increased after
adjusting for maternal race, the CI included
1.0 and the trend was not significant
(adjusted OR = 1.24; 95% CI, 0.58–2.63;
p-value for trend = 0.72).
Women whose serum DDT level was in
the highest quartile (≥ 20.0 ng/mL) had a
23% decreased risk (adjusted OR = 0.77;
95% CI, 0.41–1.44; p-value for trend = 0.62)
of giving birth to a case compared with
women whose serum DDT level was in the
lowest quartile (< 10.0 ng/mL), after adjust-
ing for cholesterol and triglycerides. After
adjusting for maternal race, the OR increased
and the CI became wider (adjusted OR =
0.89; 95% CI, 0.46–1.72; p-value for trend =
0.98) (Table 4).
Similar results were found for analyses
where the case group was disaggregated by cryp-
torchidism and hypospadias (Tables 3 and 4).
When we dichotomized the exposure variables,
combining the two higher quartiles together and
comparing them to the two lower quartiles, we
did ﬁnd one signiﬁcant association. After adjust-
ing for cholesterol, triglyceride level, and mater-
nal race, babies whose mothers had serum levels
greater than or equal to 15.0 ng/mL DDT had
nearly two times the risk of cryptorchidism
compared with those whose mother’s serum lev-
els were less than 15.0 ng/mL DDT (adjusted
OR = 1.97; 95% CI, 1.40–2.54).
We found no evidence of confounding;
inclusion of the potential confounders separately
and together in regression models did not mate-
rially change the ORs for the effect of DDT
or DDE on hypospadias or cryptorchidism.
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Table 1. Characteristics of mothers and male offspring in a nested case–control study of U.S. participants
in the CHDS, 1959–1967.
Cryptorchidism Hypospadias Controls
Characteristics cases (n = 75) cases (n = 66) (n = 283)
Maternal characteristics
Mean ± SD [age (years)] 27.9 ± 6.5 26.4 ± 6.0 26.6 ± 6.2
Race [no. (%)]
White 46 (61.3) 49 (74.2) 173 (61.1)
Latino 1 (1.3) 1 (1.5) 9 (3.2)
Black 21 (28.0) 9 (13.6) 82 (29.0)
Asian 5 (6.7) 4 (6.1) 10 (3.5)
Other 1 (1.3) 1 (1.5) 7 (2.5)
Unknown 1 (1.3) 2 (3.0) 2 (0.7)
Highest level of education completed [no. (%)]
< 12th grade 14 (18.7) 9 (13.6) 50 (17.7)
High school graduate/trade school 44 (58.7) 37 (56.0) 160 (56.5)
College graduate 13 (17.3) 10 (15.2) 38 (13.4)
Unknown 4 (5.3) 10 (15.2) 35 (12.4)
Household income [no. (%)]
< $5,000 15 (20.0) 10 (15.2) 45 (15.9)
$5,000–9,999 32 (42.7) 31 (47.0) 119 (42.0)
$10,000–14,999 10 (13.3) 9 (13.6) 38 (13.4)
≥ $15,000 2 (2.7) 1 (1.5) 3 (1.1)
Unknown 16 (21.4) 15 (22.8) 78 (27.5)
Ever smoked [no. (%)]
Yes 31 (41.3) 28 (42.4) 117 (41.3)
No 36 (48.0) 27 (40.9) 111 (39.2)
Unknown 8 (10.7) 11 (16.7) 55 (19.4)
Years lived on a farm before age 15 [no. (%)]
None 37 (49.3) 39 (59.1) 142 (50.2)
1–4 5 (6.7) 6 (9.1) 19 (6.7)
≥ 5 14 (18.7) 4 (6.1) 34 (12.0)
Unknown 19 (25.3) 17 (25.8) 88 (31.1)
Maternal place of birth [no. (%)]
California 30 (40.0) 24 (36.4) 85 (30.0)
Southeastern United States 15 (20.0) 7 (10.6) 66 (23.3)
Other U.S. states 20 (26.7) 18 (27.3) 73 (25.8)
Non-United States 6 (8.0) 7 (10.6) 24 (8.5)
Unknown 4 (5.3) 10 (15.2) 35 (12.4)
Parity [no. (%)]
0 24 (32.0) 22 (33.3) 84 (29.7)
1–2 29 (38.7) 30 (45.5) 113 (39.9)
≥ 3 21 (28.0) 12 (18.2) 78 (27.6)
Unknown 1 (1.3) 2 (3.0) 8 (2.8)
Median [IQR] prepregnancy BMI (kg/m2) 22 [20–25] 21 [20–24] 21 [20–24]
Median [IQR] age at menarche (years) 13 [12–13] 12 [11–13] 12 [11–13]
Child’s characteristics
Season of birth [no. (%)]
January–March 17 (22.7) 23 (34.8) 65 (23.0)
April–June 20 (26.7) 12 (18.2) 68 (24.0)
July–September 22 (29.3) 18 (27.3) 70 (24.7)
October–December 16 (21.3) 13 (19.7) 80 (28.3)
Method of delivery [no. (%)]
Vaginal 74 (98.7) 62 (93.9) 274 (96.8)
Cesarian 1 (1.3) 4 (6.1) 9 (3.2)
Small for gestational age [no. (%)] 6 (8.0) 9 (13.6) 36 (12.7)
Preterm birth [no. (%)] 2 (2.7) 3 (4.5) 21 (7.4)
Median [IQR] gestational age (weeks) 40 [39–41] 40 [38–41] 40 [29–41]
Median [IQR] birth weight (g) 3,374 [3,048–3,671] 3,260 [2,948–3,622] 3,345 [3,005–3,657]
IQR, interquartile range.There was no association between the
DDE:DDT ratio and risk of either hypo-
spadias (adjusted OR comparing DDE:DDT
ratio ≥ 6.0 to < 3.0 = 1.2; 95% CI, 0.5–2.9;
p-value for trend = 0.96) or cryptorchidism
(adjusted OR comparing DDT:DDE ratio
≥ 6.0 to < 3.0 = 0.9; 95% CI, 0.3–2.3;
p-value for trend = 0.49).
Discussion
Our analysis did not ﬁnd a statistically signiﬁ-
cant adverse association between maternal
serum measures of DDT or DDE and cryp-
torchidism or hypospadias among pregnancies
enrolled in the CHDS in California in the
1960s, when levels of exposure were consider-
ably higher than they are today. The results of
our study are consistent with those reported
on hypospadias and cryptorchidism and
DDE in archived maternal serum from the
Collaborative Perinatal Project, a study con-
ducted concurrently with the CHDS. The
Collaborative Perinatal Project found that
after adjusting for maternal race, triglyceride
level, and cholesterol level, compared with
boys whose mothers had serum DDE levels in
the lowest quintile (< 21.4 ng/mL), boys
whose mothers had serum DDE levels in the
highest quintile (≥ 85.6 ng/mL) had ORs of
1.3 (95% CI, 0.7–2.4) for cryptorchidism
and 1.2 (95% CI, 0.6–2.4) for hypospadias
(Longnecker et al. 2002). Although our cut
points differed from those in the Collabo-
rative Perinatal Project, our results were com-
parable, with adjusted OR comparing boys
whose mothers had serum DDE levels in
the highest quartile (≥ 61.0 ng/mL) to boys
whose mothers had serum DDE levels in the
lowest quartile (< 27.0 ng/mL) at 1.34 (95%
CI, 0.51–3.48) for cryptorchidism and 1.18
(95% CI, 0.46–3.02) for hypospadias. The
similarity in the results between these two
studies was found despite differences in the
geographic location of the subjects (northern
California vs. 12 centers across the United
States), participants’ health care services (pre-
paid health plan vs. university-based practice),
and case inclusion criteria (cryptorchidism
present after 2 years of age vs. cryptorchidism
diagnosed in ﬁrst year of life).
Our study had several strengths. It sampled
a population from a large prospective cohort
study undertaken at a single site with excellent
subject retention and reliable information on a
number of relevant covariates. Only two sub-
jects in our sample had used hormones in the
interval from 6 months before the last men-
strual period up to the pregnancy, so the sam-
ple was not subject to bias because of the
effects of hormone use.
The study had consistent procedures for
identifying and conﬁrming congenital anom-
alies. Testicular descent is a dynamic process in
that the prevalence of undescended testes may
decrease with age (John Radcliffe Hospital
Cryptorchidism Study Group 1992). Unlike
the Collaborative Perinatal Project (Longnecker
et al. 2002), the CHDS coded cases of cryp-
torchidism only if observed for 2 years, which
allowed for spontaneous testicular descent and
decreased the possibility of case misclassiﬁca-
tion. However, we could not exclude cases of
cryptorchidism ﬁrst observed after 1 year of age,
which may have lead to a misdiagnosis
of “retractile testes.” Nevertheless, the preva-
lence of cryptorchidism in the CHDS and
Collaborative Perinatal Project studies was
identical (1.08%), although the prevalence of
hypospadias in the Collaborative Perinatal
Project was about 25% higher (0.96 vs.
0.78%). Any misclassiﬁcation of cases would be
nondifferential with respect to exposure and
would therefore attenuate any ﬁndings of an
association.
The CHDS enrolled subjects at a time of
high U.S. use of organochlorine insecticides
(Kutz et al. 1991). Serum measures of DDE
found in this study (43 ng/mL or 5.2 µg/g
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Table 2. Serum concentration distributions for organochlorine compounds in a nested case–control study
of U.S. participants in the CHDS, 1959–1967.
Cryptorchidism cases Hypospadias cases Controls
Serum measures [n = 75; median (IQR)] [n = 66; median (IQR)] [n = 283; median (IQR)]
DDE serum concentration (ng/mL) 43.0 (32.0–60.0) 41.0 (30.2–57.8) 43.0 (32.0–56.5)
DDE, lipid adjusted (µg/g lipid) 5.3 (3.9–7.3) 4.6 (3.5–6.6) 5.2 (3.8–6.9)
DDT serum concentration (ng/mL) 12.1 (8.7–18.1) 9.5 (7.5–14.2) 11.1 (8.4–16.1)
DDT, lipid adjusted (µg/g lipid) 1.4 (1.0–2.0) 1.2 (0.9–1.6) 1.4 (1.0–1.9)
Serum cholesterol concentration (g/L) 2.5 (2.1–3.0) 2.6 (2.2–3.0) 2.5 (2.1–3.0)
Serum triglycerides concentration (g/L) 1.7 (1.4–2.4) 2.1 (1.5–2.6) 1.8 (1.4–2.3)
Total serum lipid concentration (g/L) 8.0 (6.7–9.5) 8.6 (7.3–9.9) 8.1 (7.0–9.5)
IQR, interquartile range.
Table 3. Adjusted ORs (95% CI) for birth defects among male offspring by DDE level in mother’s serum,
CHDS, 1959–1967.
DDE (ng/mL serum) No. of Cases No. of Controls Adjusteda OR (95% CI) Adjustedb OR (95% CI)
All cases
< 27.0 21 42 Reference Reference
27.0–43.9 53 107 0.95 (0.50–1.77) 0.99 (0.52–1.89)
44.0–60.9 35 83 0.79 (0.41–1.55) 0.86 (0.43–1.70)
≥ 61.0 28 51 1.02 (0.50–2.09) 1.24 (0.58–2.63)
p-Value for trend 0.89 0.72
Cryptorchidism
< 27.0 10 42 Reference Reference
27.0–43.9 30 107 1.16 (0.52–2.60) 1.17 (0.51–2.66)
44.0–60.9 19 83 0.94 (0.40–2.24) 0.95 (0.39–2.30)
≥ 61.0 16 51 1.29 (0.52–3.22) 1.34 (0.51–3.48)
p-Value for trend 0.77 0.75
Hypospadias
< 27.0 12 42 Reference Reference
27.0–43.9 24 107 0.73 (0.33–1.62) 0.81 (0.36–1.84)
44.0–60.9 16 83 0.61 (0.26–1.43) 0.68 (0.28–1.64)
≥ 61.0 14 51 0.86 (0.35–2.10) 1.18 (0.46–3.02)
p-Value for trend 0.7 0.82
aAdjusted for cholesterol and triglyceride levels. bAdjusted for cholesterol level, triglyceride level, and maternal race.
Table 4. Adjusted ORs (95% CI) for birth defects among male offspring by DDT level in mother’s serum,
CHDS, 1959–1967.
DDE (ng/mL serum) No. of Cases No. of Controls Adjusteda OR (95% CI) Adjustedb OR (95% CI)
All cases
< 10.0 65 117 Reference Reference
10.0–14.9 29 87 0.59 (0.35–0.99) 0.63 (0.37–1.07)
15.0–19.9 24 37 1.13 (0.62–2.06) 1.25 (0.66–2.36)
≥ 20.0 19 42 0.77 (0.41–1.44) 0.89 (0.46–1.72)
p-Value for trend 0.62 0.98
Cryptorchidism
< 10.0 32 117 Reference Reference
10.0–14.9 12 87 0.50 (0.24–1.02) 0.49 (0.23–1.01)
15.0–19.9 20 37 1.95 (0.99–3.83) 2.04 (1.00–4.18)
≥ 20.0 11 42 0.95 (0.43–2.07) 1.01 (0.44–2.28)
p-Value for trend 0.42 0.38
Hypospadias
< 10.0 34 117 Reference Reference
10.0–14.9 18 87 0.70 (0.37–1.32) 0.81 (0.42–1.56)
15.0–19.9 5 37 0.45 (0.16–1.24) 0.45 (0.16–1.28)
≥ 20.0 9 42 0.66 (0.28–1.52) 0.79 (0.33–1.89)
p-Value for trend 0.15 0.30
aAdjusted for cholesterol and triglyceride levels. bAdjusted for cholesterol level, triglyceride level, and maternal race.Children’s Health | Bhatia et al.
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lipid) are comparable with those estimated from
samples of body fat during the late 1960s and
are among the highest recorded in U.S. popula-
tions (Kutz et al. 1991). Our results are compa-
rable with measures of DDE (54 ng/mL or
6.9 µg/g lipid) from another analysis of CHDS
archived maternal serum (James et al. 2002) as
well as with those (43 ng/mL) found in an
analysis of archived serum collected between
1964 and 1971 in northern California (Krieger
et al. 1994). Notably, the CHDS mothers had
DDE levels that were higher than the recovery-
adjusted DDE levels in the Collaborative
Perinatal Project mothers (34.3 ng/mL and
4.24 µg/g lipid) (Longnecker et al. 2002).
Serum measures in this population for
DDE are also comparable with those associated
with reproductive effects seen in eagles in their
natural environments. In a study of nestling
eagles, Bowerman et al. (1995) showed that
productivity, measured as the number of
young eagles observed in occupied nests, varied
inversely with DDE levels measured in plasma
of the same populations of eagles, which
ranged from 5 to 40 ng/g. The serum DDE
levels in our study are sufficient to inhibit
androgen activity, based on in vitro effects.
Kelce et al. (1995) found that 63.6 ng/mL
DDE was sufﬁcient to inhibit androgen recep-
tor transcriptional activity in vitro.
Our study was limited in that serum was
not available for all cases in the cohort, and this
could have resulted in a bias. If the missing cases
all had high DDT or DDE levels, then selection
bias could have caused us to miss a positive asso-
ciation. An unmeasured confounder could also
explain these results if levels of DDT or DDE
varied with a protective factor for hypospadias
or cryptorchidism. For example, ﬁsh consump-
tion may promote fetal growth, a possible pro-
tective factor against the disorders studied, and
may be associated with higher human cumula-
tive exposure to organochlorines (Olsen and
Secher 2002; Olsen et al. 1990, 1993). Notably,
one U.S. study found no relationship between
dietary consumption of ﬁsh and serum DDE
levels (Laden et al. 1999).
Few models exist to adequately examine the
combined effects of multiple chemicals with
potential endocrine activity. Competing effects
due to environmental agents with similar
exposure pathways may obscure relationships
between cause and effect in epidemiologic stud-
ies. For example, an androgen antagonist may
oppose the effects of an estrogen agonist on the
human pituitary because both androgens and
estrogens inhibit luteinizing hormone secretion.
Similarly, if DDE and DDT have differing
effects, they could oppose each other and
obscure any direct associations with adverse
outcomes.
In summary, our study does not provide
epidemiologic support for a causal adverse
relationship between DDT or DDE and
cryptorchidism or hypospadias. Our sample
size was adequate to identify an approximate
doubling of risk for the outcomes under study
relative to the range of serum measures; how-
ever, the study may lack sufficient power to
find a more modest effect with the observed
exposure levels. Overall, DDT and DDE
remain appropriate candidates for the study
of environmental endocrine effects, especially
given their wide use, their environmental per-
sistence, their documented adverse reproduc-
tive effects in animals, and effects on other
reproductive outcomes. Although this study
does not support an association of DDT or
DDE and hypospadias and cryptorchidism,
the continued use of DDT in vector control
in developing countries and its global distrib-
ution warrant further inquiry.
REFERENCES
Baskin LS, Himes K, Colborn T. 2001. Hypospadias and endocrine
disruption: is there a connection? Environ Health Perspect
109:1175–1183.
Beard CM, Melton LJ III, O’Fallon WM, Noller KL, Benson RC.
1984. Cryptorchism and maternal estrogen exposure. Am J
Epidemiol 120:707–716.
Berkowitz GS, Lapinski RH, Godbold JH, Dolgin SE, Holzman IR.
1995. Maternal and neonatal risk factors for cryptorchidism.
Epidemiology 6:127–131.
Bowerman WW, Giesy JP, Best DA, Kramer VJ. 1995. A review
of factors affecting productivity of bald eagles in the Great
Lakes region: implications for recovery. Environ Health
Perspect 103(suppl 4):51–59.
Bulger WH, Kupfer D. 1983. Estrogenic action of DDT analogs.
Am J Ind Med 4:163–173.
Christianson RE, van den Berg BJ, Milkovich L, Oechsli FW.
1981. Incidence of congenital anomalies among white and
black live births with long-term follow-up. Am J Public
Health 71:1333–1341.
Clarkson TW. 1995. Environmental contaminants in the food
chain. Am J Clin Nutr 61(3 suppl):682S—686S.
Cosgrove MD, Benton B, Henderson BE. 1977. Male genitouri-
nary abnormalities and maternal diethylstilbestrol. J Urol
117:220–221.
Danzo BJ. 1997. Environmental xenobiotics may disrupt normal
endocrine function by interfering with the binding of physio-
logical ligands to steroid receptors and binding proteins.
Environ Health Perspect 105:294–301.
Depue RH. 1984. Maternal and gestational factors affecting the
risk of cryptorchidism and inguinal hernia. Int J Epidemiol
13:311–318.
Facemire CF, Gross TS, Guillette LJ Jr. 1995. Reproductive impair-
ment in the Florida panther: nature or nurture? Environ
Health Perspect 103(suppl 4):79–86.
Fry DM, Toone CK. 1981. DDT-induced feminization of gull
embryos. Science 213:922–924.
García-Rodríguez J, García-Martín M, Nogueras-Ocaña M,
Luna-del-Castillo J, García ME, Olea N, et al. 1996.
Exposure to pesticides and cryptorchidism: geographical
evidence of a possible association. Environ Health
Perspect 104:1090–1095.
Gill WB, Schumacher FB, Bibbo M, Straus FH, Schoenberg HW.
1979. Association of diethylstilbestrol exposure in utero
with cryptorchidism, testicular hypoplasia, and semen
abnormalities. J Urol 122:36–39.
Gray LE Jr, Ostby J, Furr J, Wolf CJ, Lambright C, Parks L, et al.
2001. Effects of environmental antiandrogens on reproduc-
tive development in experimental animals. Hum Reprod
Update 7:248–264.
Guillette LJ Jr, Gross TS, Gross DA, Rooney AA, Percival HF.
1995. Gonadal steroidogenesis in vitro from juvenile alliga-
tors obtained from contaminated or control lakes. Environ
Health Perspect 103(suppl 4):31–36.
Guillette LJ Jr, Guillette EA. 1996. Environmental contaminants
and reproductive abnormalities in wildlife: implications for
public health? Toxicol Ind Health 12:537–550.
Hjertkvist M, Damber JE, Bergh A. 1989. Cryptorchidism: a reg-
istry based study in Sweden on some factors of possible
aetiological importance. J Epidemiol Community Health
42:324–329.
Jackson MB. 1988. The epidemiology of cryptorchidism. John
Radcliffe Hospital Cryptorchidism Research Group. Horm
Res 30:153–156.
James RA, Hertz-Picciotto I, Willman E, Keller JA, Charles MJ.
2002. Determinants of serum polychlorinated biphenyls and
organochlorine pesticides measured in women from the
Child Health and Development Study Cohort, 1963–1967.
Environ Health Perspect 110:617–624.
John Radcliffe Hospital Cryptorchidism Study Group. 1992.
Cryptorchidism: a prospective study of 7500 consecutive
male births, 1984–8. Arch Dis Child 67:892–899.
Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA,
Wilson EM. 1995. Persistent DDT metabolite p,p´-DDE is a
potent androgen receptor antagonist. Nature 375:581–585.
Krieger N, Wolff MS, Hiatt RA, Rivera M, Vogelman J,
Orentreich N. 1994. Breast cancer and serum organochlo-
rines: a prospective study among white, black, and Asian
women. J Natl Cancer Inst. 86:589–599.
Kutz FW, Wood PH, Bottimore DP. 1991. Organochlorine pesti-
cides and polychlorinated biphenyls in human adipose tissue.
Rev Environ Contam Toxicol 120:1–82.
Laden F, Neas LM, Spiegelman D, Hankinson SE, Willett WC,
Ireland K, et al. 1999. Predictors of plasma concentrations
of DDE and PCBs in a group of U.S. women. Environ Health
Perspect 107:75–81.
Landrigan P, Garg A, Droller DBJ. 2003. Assessing the effects
of endocrine disruptors in the National Children’s Study.
Environ Health Perspect 111:1678–1682.
Longnecker MP, Klebanoff MA, Brock JW, Zhou H, Gray KA,
Needham LL, et al. 2002. Maternal serum level of 1,1-
dichloro-2,2-bis(p-chlorophenyl)ethylene and risk of cryp-
torchidism, hypospadias, and polythelia among male
offspring. Am J Epidemiol 155:313–322.
Longnecker MP, Klebanoff MA, Gladen BC, Berendes HW. 1999.
Serial levels of serum organochlorines during pregnancy
and postpartum. Arch Environ Health 54:110–114.
McBride ML, van den Steen N, Lamb CW, Gallagher RP. 1991.
Maternal and gestational factors in cryptorchidism. Int J
Epidemiol 20:964–970.
Olsen SF, Grandjean P, Weihe P, Videro T. 1993. Frequency of
seafood intake in pregnancy as a determinant of birth
weight: evidence for a dose dependent relationship.
J Epidemiol Community Health 47:436–440.
Olsen SF, Olsen J, Frische G. 1990. Does ﬁsh consumption during
pregnancy increase fetal growth? A study of the size of the
newborn, placental weight and gestational age in relation
to fish consumption during pregnancy. Int J Epidemiol
19:971–977.
Olsen SF, Secher NJ. 2002. Low consumption of seafood in early
pregnancy as a risk factor for preterm delivery: prospective
cohort study [Abstract]. Br Med J 324:447.
Paulozzi LJ. 1999. International trends in rates of hypospadias
and cryptorchidism. Environ Health Perspect 107:297–302.
Petreas M, She J, Brown FR, Winkler J, Windham G, Rogers E,
et al. 2003. High body burdens of 2,2´,4,4´-tetrabromodiphenyl
ether (BDE-47) in California women. Environ Health Perspect
111:1175–1180.
Phillips DL, Pirkle JL, Burse VW, Bernert JT Jr, Henderson LO,
Needham LL. 1989. Chlorinated hydrocarbon levels in
human serum: effects of fasting and feeding. Arch Environ
Contam Toxicol 18:495–500.
Sharpe RM, Skakkebaek NE. 1993. Are oestrogens involved in
falling sperm counts and disorders of the male reproductive
tract? Lancet 341:1392–1395.
Subramanian AN, Tanabe S, Tatsukawa R, Saito S, Miyazak N.
1987. Reduction in the testosterone levels by PCBs and
DDE in Dall’s porpoises of northwestern North Pacific.
Mar Pollut Bull 18:643–646.
Sweet RA, Schrott HG, Kurland R, Culp OS. 1974. Study of the inci-
dence of hypospadias in Rochester, Minnesota, 1940–1970,
and a case-control comparison of possible etiologic factors.
Mayo Clin Proc 49:52–57.
Swerdlow AJ, Wood KH, Smith PG. 1983. A case-control study
of the aetiology of cryptorchidism. J Epidemiol Community
Health 37:238–244.
Toppari J, Larsen JC, Christiansen P, Giwercman A, Grandjean P,
Guillette LJ Jr, et al. 1996. Male reproductive health and
environmental xenoestrogens. Environ Health Perspect
104(suppl 4):741–803.
van den Berg BJ, Christianson RE, Oechsli FW. 1988. The
California Child Health and Development Studies of the
School of Public Health, University of California at Berkeley.
Paediatr Perinat Epidemiol 2:265–282.
Wilson JD, Foster DW. 1985. Williams Textbook of Endocrinology.
7th ed. Philadelphia:W.B. Saunders.
WHO. 1957. Manual of the International Statistical Classiﬁcation
of Diseases, Injuries, and Causes of Death, 7th Revision.
Geneva:World Health Organization.